ENGINEERING OF NEW BINDING SPECIFICITIES OF PROTEIN A

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 13620
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Awards Year: 1990
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
Genex Corp
16020 Industrial Dr, Gaithersburg, MD, 20877
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 David R Filpula
 (301) 258-0552
Business Contact
Phone: () -
Research Institution
N/A
Abstract
THE OBJECTIVE OF THIS RESEARCH IS TO USE PROTEIN ENGINEERING TO GENERATE STAPHYLOCOCCAL PROTEIN A VARIANTS THAT POSSESS STRONG BINDING AFFINITY FOR IMMUNOGLOBULIN SPECIES THAT ARE NOT SIGNIFICANTLY BOUND BY NATURAL PROTEIN A. THE EXPERIMENTAL PROGRAM WILL INVOLVE A SEQUENTIAL SERIES OF EXPERIMENTS OF INCREASING LEVELS OF DIFFICULTY ENCOMPASSING STRUCTURAL DESIGN, VARIANT CONSTRUCTION, AND TESTING OF IMMUNOGLOBULIN BINDING. BASED ON THE EXISTING PROTEIN A/IMMUNOGLOBULIN FC COCRYSTAL STRUCTURE, COMPUTER MODELING AND GENETIC ENGINEERING TECHNOLOGIES WILL BE USED TO DESIGN AND PRODUCE PROTEIN A VARIANTS WITH HIGH ENGINEERED AFFINITY FOR (1) HUMAN IGG3, (2) MOUSE IGG1, AND (3) HUMAN IGM FOR THE CLINICAL DIAGNOSTICS AND THERAPEUTICS MARKET. IF SUCCESSFUL, THIS MODIFICATION OF THE BINDING SPECIFICITY OF A PROTEIN-PROTEIN COMPLEX WILL BE A MILESTONE IN THE DEVELOPMENT OF PROTEIN ENGINEERING AND WILL ALSO SERVE AS A PREFACE TO THE ENGINEERING OF PROTEIN A VARIANTS THAT BIND OTHER IMMUNOGLOBULIN CLASSES, E.G., IGE, IGD, AND IGA. THE ENGINEERED AFFINITY PROTEIN FOR HUMAN IGM WILL HAVE UTILITY AS A DIAGNOSTIC REAGENT FOR ANTIGEN-SPECIFIC IGM AND AS A THERAPEUTIC IN EXTRACORPOREAL BLOOD FILTRATION FOR DISEASES INCLUDING CANCER AND AIDS.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government